Intermittent versus continuous androgen suppression for prostatic cancer.

Area of Science:

• Urology
• Oncology
• Clinical Trials

Background:

• Prostate cancer is a leading cause of cancer death in men.
• Androgen suppression therapy (AST) is a standard treatment for advanced prostate cancer.
• The use of AST for early-stage disease is increasing despite limited evidence.

Purpose of the Study:

• To evaluate the effectiveness and safety of intermittent androgen suppression (IAS) compared to continuous androgen suppression (CAS) in prostate cancer treatment.
• To analyze outcomes including biochemical progression and adverse events.

Main Methods:

• Systematic review of randomized or quasi-randomized controlled trials.
• Searched databases: Cochrane Central Register of Controlled Trials, EMBASE, and LILACS.
• Two reviewers assessed study quality and extracted data.

Main Results:

• Five trials with 1382 patients were included, all focusing on advanced prostate cancer.
• No significant difference in biochemical progression for Gleason scores 4-10, but favored IAS for Gleason > 6.
• IAS showed a significant reduction in impotence compared to CAS, with no difference in other adverse events.

Conclusions:

• Limited data from small, short-duration trials restrict definitive conclusions on IAS vs. CAS effectiveness for survival or disease progression.
• IAS may offer a slight reduction in adverse events, particularly impotence.
• IAS appears as effective as CAS for potency, with superiority noted during treatment intervals.